A voluminous mass as an initial clinical symptom of multiple myeloma: A case report
- Authors:
- Nicola Sgherza
- Angela Iacobazzi
- Angelantonio Cramarossa
- Giacoma De Tullio
- Attilio Guarini
View Affiliations
Affiliations: Hematology Unit, National Cancer Research Center, Istituto Tumori ‘Giovanni Paolo II’, Bari 70124, Italy, Radiology Unit, National Cancer Research Center, Istituto Tumori ‘Giovanni Paolo II’, Bari 70124, Italy
- Published online on: September 1, 2015 https://doi.org/10.3892/etm.2015.2720
-
Pages:
1689-1691
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Extramedullary multiple myeloma (EMM) is a type of multiple myeloma (MM) that is defined by the presence of extraskeletal (soft tissue or visceral) clonal plasma cell infiltrates, which may be present at the time of initial diagnosis or at the time of relapse. Although extramedullary lesions may be present with other clinical features at the time of diagnosis, the onset of a solid formation as a first clinical symptom of MM is unusual. The present study reports the case of a 77‑year‑old male who was admitted to the Hematology Unit of the National Cancer Research Center, Istituto Tumori ‘Giovanni Paolo II’ (Bari, Italy) with a mass protruding from the right side of his lower back. Serum immunofixation revealed positivity for monoclonal protein (M‑protein) and Bence Jones proteinuria was positive. In addition, a computed tomography scan of the abdomen, which was confirmed by magnetic resonance imaging, revealed a voluminous solid formation resembling a sarcoma. M‑protein is known to be present in numerous diseases encountered in clinical practice, including hematological or other diseases; thus, a Tru‑Cut biopsy of the lesion was performed, which revealed an infiltration of plasma cells. In addition, a bone marrow biopsy revealed the presence of 70% plasma cells, and a diagnosis of primary EMM was established. In conclusion, EMM should be included in the differential diagnosis of a mass, particularly in patients where M‑protein is detected in the blood and/or urine.
View References
|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. 2010.CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent Rajkumar S: Treatment of multiple
myeloma. Nat Rev Clin Oncol. 8:479–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harousseau JL, Shaughnessy J Jr and
Richardson P: Multiple myeloma. Hematology Am Soc Hematol Educ
Program. 237–256. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weber DM: Solitary bone and extramedullary
plasmacytoma. Hematology Am Soc Hematol Educ Program. 373–376.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Usmani SZ, Heuck C, Mitchell A, Szymonifka
J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, et
al: Extramedullary disease portends poor prognosis in multiple
myeloma and is over-represented in high-risk disease even in the
era of novel agents. Haematologica. 97:1761–1767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vincent Rajkumar S: Multiple myeloma: 2014
Update on diagnosis, risk-stratification, and management. Am J
Hematol. 89:999–1009. 2014.PubMed/NCBI
|
|
7
|
Pour L, Sevcikova S, Greslikova H, Kupska
R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P,
et al: Soft-tissue extramedullary multiple myeloma prognosis is
significantly worse in comparison to bone-related extramedullary
relapse. Haematologica. 99:360–364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oriol A: Multiple myeloma with
extramedullary disease. Adv Ther. 28(Suppl 7): 1–6. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varettoni M, Corso A, Pica G,
Mangiacavalli S, Pascutto C and Lazzarino M: Incidence, presenting
features and outcome of extramedullary disease in multiple myeloma:
A longitudinal study on 1003 consecutive patients. Ann Oncol.
21:325–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
International Myeloma Working Group:
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
International Myeloma Working Group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mena E, Choyke P, Tan E, Landgren O and
Kurdziel K: Molecular imaging in myeloma precursor disease. Semin
Hematol. 48:22–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ghanem N, Lohrmann C, Engelhard M, Pache
G, Uhl M, Saueressig U, Kotter E and Langer M: Whole-body MRI in
the detection of bone marrow infiltration in patients with plasma
cell neoplasms in comparison to the radiological skeletal survey.
Eur Radiol. 16:1005–1014. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Durie BG, Waxman AD, DAgolo A and Williams
CM: Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl
Med. 43:1457–1463. 2002.PubMed/NCBI
|
